A 12-month prospective real-life study of opicapone efficacy and tolerability in Emirati and non-White subjects with Parkinson’s disease based in United Arab Emirates

Vinod Metta; Huzaifa Ibrahim; Neha Muralidharan; Kislyn Rodriguez; Therese Masagnay; Judith Mohan; Arlet Lacsina; Abdullah Ahmed; Hani T.S. Benamer; Guy Chung-Faye; Rukmini Mrudula; Cristian Falup-Pecurariu; Carmen Rodriguez-Blazquez; Rupam Borgohain; Vinay Goyal; Kalyan Bhattacharya; K. Ray Chaudhuri

doi:10.1007/s00702-023-02700-y

A 12-month prospective real-life study of opicapone efficacy and tolerability in Emirati and non-White subjects with Parkinson’s disease based in United Arab Emirates

Vinod Metta^*, Huzaifa Ibrahim, Neha Muralidharan, Kislyn Rodriguez, Therese Masagnay, Judith Mohan, Arlet Lacsina, Abdullah Ahmed, Hani T.S. Benamer, Guy Chung-Faye, Rukmini Mrudula, Cristian Falup-Pecurariu, Carmen Rodriguez-Blazquez, Rupam Borgohain, Vinay Goyal, Kalyan Bhattacharya, K. Ray Chaudhuri

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

Parkinson’s disease (PD) is the second most common neurodegenerative disorder, and the condition is complicated by the emergence of wearing off/motor fluctuations with levodopa treatment after a variable period. COMT inhibitors when used as adjunct therapy to levodopa tend to smoothen out these wearing off fluctuations by enhancing delivery of levodopa and increasing its bioavailability to the brain. The study was conducted to investigate the motor and nonmotor effect, safety and tolerability of the third generation once-daily COMT inhibitor (opicapone), as add-on, adjuvant therapy to levodopa and at 6 and 12 months follow-up in a real-life cohort of consecutive Emirati and non-White PD patients. A real-life observational analysis using tolerability parameters as used previously by Rizos et al. and Shulman et al. based on clinical database of cases rat Kings College Hospital Dubai Parkinson care database. This was a prospective, single-arm follow-up clinical evaluation study that evaluated the effectiveness of opicapone 50 mg once-daily regime in 50 patients diagnosed with idiopathic neurodegenerative disorder. All patients were assessed with scales used in clinical pathway and include motor Unified Parkinson’s Disease Rating Scale (UPDRS), nonmotor symptom scale (NMSS), quality of life (PDQ8) Parkinson’s fatigue scale (PFS16) and King’s Parkinson’s Pain Scale (KIPS). Out of 50 patients treated with opicapone (72% male, mean age 66.9 years (SD 9.9, range 41–82 years) and mean duration of disease 5.7 years (SD 2.5 range (2–11), there was significant statistical improvements shown in motor function-UPDRS part 3: baseline 40.64 ± 2.7, at 6 months 32.12 ± 3.14 and after 12 months 33.72 ± 3.76. Nonmotor burden NMSS: 107.00 ± 21.86, at 6 months 100.78 ± 17.28 and 12 months 96.88 ± 16.11. Reduction in dyskinesias (UPDRS part 4): baseline 8.78 ± 1.07, at 6 months 7.4 ± 0.81 and 12 months 6.82 ± 0.75. Opicapone provides beneficial motor and nonmotor effects in Emirati and other non-White Parkinson’s patients, resident in UAE, proving its efficacy across different racial groups as COMT activity may vary between races.

Original language	English
Pages (from-to)	25-30
Number of pages	6
Journal	Journal of Neural Transmission
Volume	131
Issue number	1
DOIs	https://doi.org/10.1007/s00702-023-02700-y
Publication status	Published - Jan 2024

Keywords

Catechol-O-methyltransferase
Entacapone
Nonmotor symptoms
Opicapone

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00702-023-02700-y

Cite this

Metta, V., Ibrahim, H., Muralidharan, N., Rodriguez, K., Masagnay, T., Mohan, J., Lacsina, A., Ahmed, A., Benamer, H. T. S., Chung-Faye, G., Mrudula, R., Falup-Pecurariu, C., Rodriguez-Blazquez, C., Borgohain, R., Goyal, V., Bhattacharya, K., & Chaudhuri, K. R. (2024). A 12-month prospective real-life study of opicapone efficacy and tolerability in Emirati and non-White subjects with Parkinson’s disease based in United Arab Emirates. Journal of Neural Transmission, 131(1), 25-30. https://doi.org/10.1007/s00702-023-02700-y

@article{2cae028a9f49495297d73d07799dd92b,

title = "A 12-month prospective real-life study of opicapone efficacy and tolerability in Emirati and non-White subjects with Parkinson{\textquoteright}s disease based in United Arab Emirates",

abstract = "Parkinson{\textquoteright}s disease (PD) is the second most common neurodegenerative disorder, and the condition is complicated by the emergence of wearing off/motor fluctuations with levodopa treatment after a variable period. COMT inhibitors when used as adjunct therapy to levodopa tend to smoothen out these wearing off fluctuations by enhancing delivery of levodopa and increasing its bioavailability to the brain. The study was conducted to investigate the motor and nonmotor effect, safety and tolerability of the third generation once-daily COMT inhibitor (opicapone), as add-on, adjuvant therapy to levodopa and at 6 and 12 months follow-up in a real-life cohort of consecutive Emirati and non-White PD patients. A real-life observational analysis using tolerability parameters as used previously by Rizos et al. and Shulman et al. based on clinical database of cases rat Kings College Hospital Dubai Parkinson care database. This was a prospective, single-arm follow-up clinical evaluation study that evaluated the effectiveness of opicapone 50 mg once-daily regime in 50 patients diagnosed with idiopathic neurodegenerative disorder. All patients were assessed with scales used in clinical pathway and include motor Unified Parkinson{\textquoteright}s Disease Rating Scale (UPDRS), nonmotor symptom scale (NMSS), quality of life (PDQ8) Parkinson{\textquoteright}s fatigue scale (PFS16) and King{\textquoteright}s Parkinson{\textquoteright}s Pain Scale (KIPS). Out of 50 patients treated with opicapone (72% male, mean age 66.9 years (SD 9.9, range 41–82 years) and mean duration of disease 5.7 years (SD 2.5 range (2–11), there was significant statistical improvements shown in motor function-UPDRS part 3: baseline 40.64 ± 2.7, at 6 months 32.12 ± 3.14 and after 12 months 33.72 ± 3.76. Nonmotor burden NMSS: 107.00 ± 21.86, at 6 months 100.78 ± 17.28 and 12 months 96.88 ± 16.11. Reduction in dyskinesias (UPDRS part 4): baseline 8.78 ± 1.07, at 6 months 7.4 ± 0.81 and 12 months 6.82 ± 0.75. Opicapone provides beneficial motor and nonmotor effects in Emirati and other non-White Parkinson{\textquoteright}s patients, resident in UAE, proving its efficacy across different racial groups as COMT activity may vary between races.",

keywords = "Catechol-O-methyltransferase, Entacapone, Nonmotor symptoms, Opicapone",

author = "Vinod Metta and Huzaifa Ibrahim and Neha Muralidharan and Kislyn Rodriguez and Therese Masagnay and Judith Mohan and Arlet Lacsina and Abdullah Ahmed and Benamer, {Hani T.S.} and Guy Chung-Faye and Rukmini Mrudula and Cristian Falup-Pecurariu and Carmen Rodriguez-Blazquez and Rupam Borgohain and Vinay Goyal and Kalyan Bhattacharya and Chaudhuri, {K. Ray}",

note = "Publisher Copyright: {\textcopyright} 2023, Crown.",

year = "2024",

month = jan,

doi = "10.1007/s00702-023-02700-y",

language = "English",

volume = "131",

pages = "25--30",

journal = "Journal of Neural Transmission",

issn = "0300-9564",

publisher = "Springer Verlag",

number = "1",

}

Metta, V, Ibrahim, H, Muralidharan, N, Rodriguez, K, Masagnay, T, Mohan, J, Lacsina, A, Ahmed, A, Benamer, HTS, Chung-Faye, G, Mrudula, R, Falup-Pecurariu, C, Rodriguez-Blazquez, C, Borgohain, R, Goyal, V, Bhattacharya, K & Chaudhuri, KR 2024, 'A 12-month prospective real-life study of opicapone efficacy and tolerability in Emirati and non-White subjects with Parkinson’s disease based in United Arab Emirates', Journal of Neural Transmission, vol. 131, no. 1, pp. 25-30. https://doi.org/10.1007/s00702-023-02700-y

TY - JOUR

T1 - A 12-month prospective real-life study of opicapone efficacy and tolerability in Emirati and non-White subjects with Parkinson’s disease based in United Arab Emirates

AU - Metta, Vinod

AU - Ibrahim, Huzaifa

AU - Muralidharan, Neha

AU - Rodriguez, Kislyn

AU - Masagnay, Therese

AU - Mohan, Judith

AU - Lacsina, Arlet

AU - Ahmed, Abdullah

AU - Benamer, Hani T.S.

AU - Chung-Faye, Guy

AU - Mrudula, Rukmini

AU - Falup-Pecurariu, Cristian

AU - Rodriguez-Blazquez, Carmen

AU - Borgohain, Rupam

AU - Goyal, Vinay

AU - Bhattacharya, Kalyan

AU - Chaudhuri, K. Ray

PY - 2024/1

Y1 - 2024/1

N2 - Parkinson’s disease (PD) is the second most common neurodegenerative disorder, and the condition is complicated by the emergence of wearing off/motor fluctuations with levodopa treatment after a variable period. COMT inhibitors when used as adjunct therapy to levodopa tend to smoothen out these wearing off fluctuations by enhancing delivery of levodopa and increasing its bioavailability to the brain. The study was conducted to investigate the motor and nonmotor effect, safety and tolerability of the third generation once-daily COMT inhibitor (opicapone), as add-on, adjuvant therapy to levodopa and at 6 and 12 months follow-up in a real-life cohort of consecutive Emirati and non-White PD patients. A real-life observational analysis using tolerability parameters as used previously by Rizos et al. and Shulman et al. based on clinical database of cases rat Kings College Hospital Dubai Parkinson care database. This was a prospective, single-arm follow-up clinical evaluation study that evaluated the effectiveness of opicapone 50 mg once-daily regime in 50 patients diagnosed with idiopathic neurodegenerative disorder. All patients were assessed with scales used in clinical pathway and include motor Unified Parkinson’s Disease Rating Scale (UPDRS), nonmotor symptom scale (NMSS), quality of life (PDQ8) Parkinson’s fatigue scale (PFS16) and King’s Parkinson’s Pain Scale (KIPS). Out of 50 patients treated with opicapone (72% male, mean age 66.9 years (SD 9.9, range 41–82 years) and mean duration of disease 5.7 years (SD 2.5 range (2–11), there was significant statistical improvements shown in motor function-UPDRS part 3: baseline 40.64 ± 2.7, at 6 months 32.12 ± 3.14 and after 12 months 33.72 ± 3.76. Nonmotor burden NMSS: 107.00 ± 21.86, at 6 months 100.78 ± 17.28 and 12 months 96.88 ± 16.11. Reduction in dyskinesias (UPDRS part 4): baseline 8.78 ± 1.07, at 6 months 7.4 ± 0.81 and 12 months 6.82 ± 0.75. Opicapone provides beneficial motor and nonmotor effects in Emirati and other non-White Parkinson’s patients, resident in UAE, proving its efficacy across different racial groups as COMT activity may vary between races.

AB - Parkinson’s disease (PD) is the second most common neurodegenerative disorder, and the condition is complicated by the emergence of wearing off/motor fluctuations with levodopa treatment after a variable period. COMT inhibitors when used as adjunct therapy to levodopa tend to smoothen out these wearing off fluctuations by enhancing delivery of levodopa and increasing its bioavailability to the brain. The study was conducted to investigate the motor and nonmotor effect, safety and tolerability of the third generation once-daily COMT inhibitor (opicapone), as add-on, adjuvant therapy to levodopa and at 6 and 12 months follow-up in a real-life cohort of consecutive Emirati and non-White PD patients. A real-life observational analysis using tolerability parameters as used previously by Rizos et al. and Shulman et al. based on clinical database of cases rat Kings College Hospital Dubai Parkinson care database. This was a prospective, single-arm follow-up clinical evaluation study that evaluated the effectiveness of opicapone 50 mg once-daily regime in 50 patients diagnosed with idiopathic neurodegenerative disorder. All patients were assessed with scales used in clinical pathway and include motor Unified Parkinson’s Disease Rating Scale (UPDRS), nonmotor symptom scale (NMSS), quality of life (PDQ8) Parkinson’s fatigue scale (PFS16) and King’s Parkinson’s Pain Scale (KIPS). Out of 50 patients treated with opicapone (72% male, mean age 66.9 years (SD 9.9, range 41–82 years) and mean duration of disease 5.7 years (SD 2.5 range (2–11), there was significant statistical improvements shown in motor function-UPDRS part 3: baseline 40.64 ± 2.7, at 6 months 32.12 ± 3.14 and after 12 months 33.72 ± 3.76. Nonmotor burden NMSS: 107.00 ± 21.86, at 6 months 100.78 ± 17.28 and 12 months 96.88 ± 16.11. Reduction in dyskinesias (UPDRS part 4): baseline 8.78 ± 1.07, at 6 months 7.4 ± 0.81 and 12 months 6.82 ± 0.75. Opicapone provides beneficial motor and nonmotor effects in Emirati and other non-White Parkinson’s patients, resident in UAE, proving its efficacy across different racial groups as COMT activity may vary between races.

KW - Catechol-O-methyltransferase

KW - Entacapone

KW - Nonmotor symptoms

KW - Opicapone

UR - http://www.scopus.com/inward/record.url?scp=85173773405&partnerID=8YFLogxK

U2 - 10.1007/s00702-023-02700-y

DO - 10.1007/s00702-023-02700-y

M3 - Article

C2 - 37798410

AN - SCOPUS:85173773405

SN - 0300-9564

VL - 131

SP - 25

EP - 30

JO - Journal of Neural Transmission

JF - Journal of Neural Transmission

IS - 1

ER -

A 12-month prospective real-life study of opicapone efficacy and tolerability in Emirati and non-White subjects with Parkinson’s disease based in United Arab Emirates

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this